← Back to patent-cliff list
Fondaparinux Sodium
Tier C — Watch / tradeFondaparinux Sodium
-
Originator
2001
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SERPINC1, PT, F10
Brand：Arixtra, Quixidar
Indications (approved)：Pulmonary embolism, Venous thrombosis, Myocardial infarction, Angina pectoris, Thromboembolism, Liver disease
Regional status
US
Approved
2001-12-07
EU
Approved
2002-03-20
China
Approved
2008-01-01
Japan
Approved
2007-04-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fondaparinux Sodium?
Approved indications include: Pulmonary embolism, Venous thrombosis, Myocardial infarction, Angina pectoris, Thromboembolism, Liver disease.
When does the Fondaparinux Sodium patent expire?
No public expiry year is available for Fondaparinux Sodium yet; this page updates once verified.
How do I get a quote for Fondaparinux Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27